KALA Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
KALA BIO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.80 |
| 52 Week High | US$10.97 |
| 52 Week Low | US$4.21 |
| Beta | -2.14 |
| 11 Month Change | -0.073% |
| 3 Month Change | 10.85% |
| 1 Year Change | 9.24% |
| 33 Year Change | -92.65% |
| 5 Year Change | -96.74% |
| Change since IPO | -99.27% |
Recent News & Updates
Recent updates
Kala Pharmaceuticals to execute reverse stock split
Oct 20Kala Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Staying Patient With Kala Pharmaceuticals
Aug 29The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts
Aug 10
Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Jul 07Shareholder Returns
| KALA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.4% | 2.5% | 2.2% |
| 1Y | 9.2% | 16.1% | 31.6% |
Return vs Industry: KALA underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: KALA underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| KALA volatility | |
|---|---|
| KALA Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KALA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KALA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 43 | Mark Iwicki | www.kalarx.com |
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
KALA BIO, Inc. Fundamentals Summary
| KALA fundamental statistics | |
|---|---|
| Market cap | US$31.31m |
| Earnings (TTM) | -US$38.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs KALA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KALA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$38.96m |
| Earnings | -US$38.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 253.8% |
How did KALA perform over the long term?
See historical performance and comparison